Recombinant PCSK9 (Bococizumab Biosimilar) antibody

Catalog No. ABIN7488036

The Mammalian Cells Monoclonal anti-PCSK9 (Bococizumab Biosimilar) antibody has been validated for ELISA. It is suitable to detect PCSK9 (Bococizumab Biosimilar) in samples from Human.

Quick Overview for Recombinant PCSK9 (Bococizumab Biosimilar) antibody (ABIN7488036)

Target: PCSK9 (Bococizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This PCSK9 (Bococizumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-PCSK9 (Bococizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Bococizumab Biosimilar - Anti-PCSK9, NARC1, PC9 mAb

Characteristics: Antibody Type: IgG2-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG2

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for PCSK9 (Bococizumab Biosimilar)

Target: PCSK9 (Bococizumab Biosimilar)

Target Type: Biosimilar

Background: PF-04950615,RN-316
Bococizumab is a monoclonal antibody that was development by Pfizer targeting proprotein convertase subtilisin kexin type 9 (PCSK9). Bococizumab has been investigated for the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia.

CAS-No: 1407495-02-6